文献速递心血管胸部CT

无症状患者冠状动脉钙化评分≥1000的长期全因与病因特异性死亡率:CAC联盟研究结果

Long-Term All-Cause and Cause-Specific Mortality in Asymptomatic Patients With CAC ≥1,000: Results From the CAC Consortium.
PubMed 文献 · JACC Cardiovasc Imaging · 2019-03-15

该研究基于CAC联盟66,636名无症状成人回顾性多中心队列,平均随访12.3±3.9年,评估CAC≥1000者的影像特征与死亡风险。CAC≥1000者2,869例,多数为4支血管钙化,与CAC 0相比全因死亡风险为2.89倍,与CAC 400-999相比为1.51倍,风险无平台期。

要点

  • CAC≥1000者多累及4支冠状动脉(平均3.5±0.6支),总钙化面积、平均钙化密度及冠外钙化均高于CAC 400-999者。
  • CAC≥1000者与CAC 0相比,心血管病死亡风险为5.04倍、冠心病为6.79倍、癌症为1.55倍、全因死亡为2.89倍。
  • CAC≥1000者与CAC 400-999者相比,心血管病死亡风险为1.71倍、冠心病为1.84倍、癌症为1.36倍、全因死亡为1.51倍。

核心结论

  • CAC≥1000代表一种独特的极高危表型,其死亡率结局与高危二级预防患者相当;未来指南应考虑将CAC≥1000列为独立风险组,可能从最积极的预防治疗中获益。

研究设计与样本

  • CAC联盟大型回顾性多中心临床队列,纳入66,636名无症状成人,CAC≥1000者2,869例(86.3%男性,平均66.3±9.7岁),平均随访12.3±3.9年,采用多变量Cox比例风险回归模型校正年龄、性别和传统危险因素。

关键影像表现/征象

  • CAC≥1000者多数为4支血管钙化(平均3.5±0.6支),总CAC面积更大、平均CAC密度更高。
  • CAC≥1000者冠外钙化更常见:79%有胸主动脉钙化、46%有主动脉瓣钙化、21%有二尖瓣钙化。
  • CAC≥1000患者的风险图形分析显示风险持续对数增长,无明确风险平台期证据。

诊断标准与关键数值

  • 以CAC 0为参照,CAC≥1000者心血管病死亡风险为5.04倍(95%CI 3.92-6.48)、冠心病为6.79倍(95%CI 4.74-9.73)、癌症为1.55倍(95%CI 1.23-1.95)、全因死亡为2.89倍(95%CI 2.53-3.31)。
  • 以CAC 400-999为参照,CAC≥1000者心血管病死亡风险为1.71倍(95%CI 1.41-2.08)、冠心病为1.84倍(95%CI 1.43-2.36)、癌症为1.36倍(95%CI 1.07-1.73)、全因死亡为1.51倍(95%CI 1.33-1.70)。
  • 当前指南将CAC>300或400归为最高风险组,但CAC≥1000者的影像特征和死亡风险具有独特性。

临床应用与阅片要点

  • 阅片时若CAC≥1000,应同时评估冠脉钙化支数、总钙化面积、平均钙化密度及冠外钙化(胸主动脉、主动脉瓣、二尖瓣)。
  • CAC≥1000者风险持续对数增长且无平台期,报告时应提示其属于极高危表型。
  • 作者认为未来指南应考虑将CAC≥1000列为独立风险组,可能从最积极的预防治疗中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study thoroughly explored the demographic and imaging characteristics, as well as the all-cause and cause-specific mortality risks of patients with a coronary artery calcium (CAC) score ≥1,000 in the largest dataset of this population to date.

BACKGROUND: CAC is commonly used to quantify cardiovascular risk. Current guidelines classify a CAC score of >300 or 400 as the highest risk group, yet little is known about the potentially unique imaging characteristics and mortality risk in individuals with a CAC score ≥1,000.

METHODS: A total of 66,636 asymptomatic adults were included from the CAC consortium, a large retrospective multicenter clinical cohort. Mean patient follow-up was 12.3 ± 3.9 years for patients with cardiovascular disease (CVD), coronary heart disease (CHD), cancer, and all-cause mortality. Multivariate Cox proportional hazards regression models adjusted for age, sex, and conventional risk factors were used to assess the relative mortality hazard of individuals with CAC ≥1,000 compared with, first, a CAC reference of 0, and second, with patients with a CAC score of 400 to 999.

RESULTS: There were 2,869 patients with CAC ≥1,000 (86.3% male, mean 66.3 ± 9.7 years of age). Most patients with CAC ≥1,000 had 4-vessel CAC (mean: 3.5 ± 0.6 vessels) and had greater total CAC area, higher mean CAC density, and more extracoronary calcium (79% with thoracic artery calcium, 46% with aortic valve calcium, and 21% with mitral valve calcium) than those with CAC scores of 400 to 999. After full adjustment, those with CAC ≥1,000 had a 5.04- (95% confidence interval [CI]: 3.92 to 6.48), 6.79- (95% CI: 4.74 to 9.73), 1.55- (95% CI:1.23 to 1.95), and 2.89-fold (95% CI: 2.53 to 3.31) risk of CVD, CHD, cancer, and all-cause mortality, respectively, compared to those with CAC score of 0. The CAC ≥1,000 group had a 1.71- (95% CI: 1.41 to 2.08), 1.84- (95% CI: 1.43 to 2.36), 1.36- (95% CI:1.07 to 1.73), and 1.51-fold (95% CI: 1.33 to 1.70) increased risk of CVD, CHD, cancer, and all-cause mortality compared to those with CAC scores 400 to 999. Graphic analysis of CAC ≥1,000 patients revealed continued logarithmic increase in risk, with no clear evidence of a risk plateau.

CONCLUSIONS: Patients with extensive CAC (CAC ≥1,000) represent a unique very high-risk phenotype with mortality outcomes commensurate with high-risk secondary prevention patients. Future guidelines should consider CAC ≥1,000 patients to be a distinct risk group who may benefit from the most aggressive preventive therapy.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Peng AW, Mirbolouk M, Orimoloye OA, et al. Long-Term All-Cause and Cause-Specific Mortality in Asymptomatic Patients With CAC ≥1,000: Results From the CAC Consortium. JACC Cardiovasc Imaging. 2019. PMID: 31005541. doi:10.1016/j.jcmg.2019.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。